Skip to main content
Premium Trial:

Request an Annual Quote

BioAnalytics Group Partners with Prescient to Develop Cardiovascular Diagnostics, Therapeutics

NEW YORK (GenomeWeb News) - The BioAnalytics Group said last week that it is collaborating with Prescient Medical to develop heart attack prevention and treatment technologies.
 
Under the agreement, the BioAnalytics Group will use its Model Based Assay biosimulation methodologies to help Prescient calibrate and optimize a Raman Spectroscopy-based diagnostic system to characterize vulnerable plaque.
 
The BioAnalytics Group also will provide statistical analysis support for the development of Prescient’s therapeutics product, particularly by helping design animal studies and human clinical trials.
 
The new collaboration extends a previous agreement between the companies.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.